Open Access

miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1

  • Authors:
    • Hui Gong
    • Lishan Fang
    • Yifan Li
    • Jihui Du
    • Bei Zhou
    • Xiu Wang
    • Hekai Zhou
    • Lingli Gao
    • Kaixin Wang
    • Juan Zhang
  • View Affiliations

  • Published online on: January 8, 2018     https://doi.org/10.3892/or.2018.6199
  • Pages: 1090-1098
  • Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNA-873 (miR‑873) has been reported to be dysregulated in a variety of malignancies, however, the biological function and underlying molecular mechanism of miR‑873 in colorectal cancer (CRC) remain unclear. In the present study we found that the expression levels of miR‑873 were markedly decreased in CRC cell lines and tissues from patients. Statistical analysis revealed that miR‑873 expression was inversely correlated with the disease stage of CRC. Kaplan‑Meier survival analysis revealed that patients with CRC with lower miR‑873 expression had shorter overall survival rates. Additionally, downregulation of miR‑873 enhanced the proliferation of CRC cells, while upregulation of miR‑873 reduced this proliferation. Furthermore, we found that tumor necrosis factor (TNF) receptor-associated factor 5 (TRAF5) and TGF‑β activated kinase 1 (MAP3K7) binding protein 1 (TAB1) were direct targets of miR‑873 in CRC cells. A luciferase assay revealed that ectopic expression of miR‑873 significantly reduced nuclear factor κB (NF‑κB) luciferase activity, while ectopic expression of miR‑873 inhibitor enhanced luciferase activity, suggesting that downregulation of miR‑873 can activate NF‑κB signaling. Therefore, our findings established a tumor-suppressive role for miR‑873 in the inhibition of CRC progression, which may be employed as a novel prognostic marker and as an effective therapeutic target for CRC.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 39 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gong H, Fang L, Li Y, Du J, Zhou B, Wang X, Zhou H, Gao L, Wang K, Zhang J, Zhang J, et al: miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1. Oncol Rep 39: 1090-1098, 2018
APA
Gong, H., Fang, L., Li, Y., Du, J., Zhou, B., Wang, X. ... Zhang, J. (2018). miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1. Oncology Reports, 39, 1090-1098. https://doi.org/10.3892/or.2018.6199
MLA
Gong, H., Fang, L., Li, Y., Du, J., Zhou, B., Wang, X., Zhou, H., Gao, L., Wang, K., Zhang, J."miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1". Oncology Reports 39.3 (2018): 1090-1098.
Chicago
Gong, H., Fang, L., Li, Y., Du, J., Zhou, B., Wang, X., Zhou, H., Gao, L., Wang, K., Zhang, J."miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1". Oncology Reports 39, no. 3 (2018): 1090-1098. https://doi.org/10.3892/or.2018.6199